Summary:
This is a multi-center, randomized, placebo-controlled, double-blind, parallel group study designed to confirm the benefits of mepolizumab treatment on moderate or severe exacerbations in chronic obstructive pulmonary disease (COPD) participants given as an add on to their optimized maintenance COPD therapy.
Qualified Participants Must:
• Participant must be at least 40 years of age at Screening Visit 1
•
Participants with a clinically documented history of COPD for at least 1 year in accordance with the definition by the American Thoracic Society or European Respiratory Society
•
Current or former cigarette smokers with a history of cigarette smoking of greater than 10 pack-years at Screening (Visit 1) calculated as (number of pack years = [number of cigarettes per day/20] multiplied by number of years smoked [For example, 20 cigarettes per day for 10 years or 10 cigarettes per day for 20 years])
Qualified Participants May Receive:
May receive reimbursement for time and travel for study participation, if you qualify